Notably, circDNA-based combination therapy induced broader transcriptional modulation compared to controls, simultaneously suppressing emerging HCC-associated oncogenic markers such as KIF, ABL1, ANXA2, and NCAPG (Figure S7B). This evidence concerns the gene ABL1 and hepatocellular carcinoma.